KRYS
Krystal Biotech Inc.
Company Overview
| Mkt Cap | $5.74B | Price | $301.15 |
| Volume | 65.10K | Change | +0.57% |
| P/E Ratio | 28.0 | Open | $302.03 |
| Revenue | $389.1M | Prev Close | $299.45 |
| Net Income | $204.8M | 52W Range | $123.03 - $319.48 |
| Div Yield | N/A | Target | $330.20 |
| Overall | 62 | Value | 65 |
| Quality | 60 | Technical | 63 |
No chart data available
About Krystal Biotech Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Latest News
Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities
Analysts Conflicted on These Healthcare Names: RxSight (RXST), Liquidia Technologies (LQDA) and Krystal Biotech (KRYS)
Krystal Biotech Earnings Call Highlights Profitable Growth
Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)
Analysts Are Bullish on These Healthcare Stocks: Krystal Biotech (KRYS), Incyte (INCY)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KRYS | $301.15 | +0.6% | 65.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |